Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. (BLCM) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
blcm · stock forecast · 9 analysts (3M) · FMP · updated Apr 12, 2025
Analyst Rating & Consensus
Based on 9 Wall Street analysts in the past 3 months
Buy
9 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.07
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.07 | ↓ 2.73% |
1-day model range: $0.07–$0.08. Peak: $0.08 (-2.73%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · BLCM · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2022-02-16 | Ladenburg Thalmann | Maintains | Buy→Buy |
| 2020-11-25 | Wells Fargo | Downgrade ↓ | Outperform→Perform |
| 2020-11-25 | Raymond James | Maintains | Outperform→Outperform |
| 2020-11-25 | Citigroup | Maintains | Neutral→Neutral |
| 2020-11-25 | Wells Fargo | Upgrade ↑ | Market Perform→Outperform |
| 2020-11-25 | Citigroup | Upgrade ↑ | Neutral→Buy |
| 2020-11-25 | Jefferies | Maintains | Buy→Buy |
| 2020-10-30 | Wells Fargo | Downgrade ↓ | Overweight→Equal Weight |
| 2020-10-29 | Wells Fargo | Downgrade ↓ | Overweight→Equal Weight |
| 2020-03-13 | Raymond James | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Bellicum Pharmaceuticals, Inc. (BLCM) stock. Of the recent 39 rating actions, 6 were upgrades and 6 were downgrades. 9 analysts currently cover BLCM.
Analyst Recommendation Trends
BLCM analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↑ 9900.0% YoY
Revenue Next Year
$2M
↑ 50.0% YoY
EPS This Year
$-4.19
EPS Next Year
$-1.07
↓ 74.4% YoY
EPS ForecastReported vs Estimated
Analysts forecast BLCM EPS of $-4.19 for the current fiscal year, based on estimates from 0 analysts. The BLCM revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The BLCM stock forecast is supported by two independent data sources: analyst consensus ratings from 9 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus BLCM price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The BLCM short-term stock prediction for tomorrow is $0.07 (-2.73%).
Bellicum Pharmaceuticals, Inc. trades on NASDAQ under the ticker BLCM. The BLCM stock outlook for 2027 is broadly positive, supported by a Buy consensus among 89% of covering analysts.
Frequently asked questions
BLCM forecast · 8 questionsAccording to 9 Wall Street analysts, the average 12-month BLCM price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.07.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.